Compare CORT & HII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CORT | HII |
|---|---|---|
| Founded | 1998 | 1886 |
| Country | United States | United States |
| Employees | N/A | 44000 |
| Industry | Biotechnology: Pharmaceutical Preparations | Marine Transportation |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 10.1B |
| IPO Year | 2001 | 2010 |
| Metric | CORT | HII |
|---|---|---|
| Price | $121.38 | $264.90 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 12 |
| Target Price | $141.00 | ★ $363.00 |
| AVG Volume (30 Days) | ★ 872.9K | 457.9K |
| Earning Date | 11-03-2026 | 10-29-2026 |
| Dividend Yield | N/A | ★ 2.08% |
| EPS Growth | N/A | ★ 10.24 |
| EPS | 0.09 | ★ 9.06 |
| Revenue | $761,407,000.00 | ★ $12,484,000,000.00 |
| Revenue This Year | $50.53 | $7.06 |
| Revenue Next Year | $48.75 | $6.38 |
| P/E Ratio | $1,317.11 | ★ $29.25 |
| Revenue Growth | ★ 12.79 | 8.23 |
| 52 Week Low | $28.66 | $256.79 |
| 52 Week High | $126.38 | $460.00 |
| Indicator | CORT | HII |
|---|---|---|
| Relative Strength Index (RSI) | 59.16 | 40.91 |
| Support Level | $108.33 | $260.20 |
| Resistance Level | $123.01 | $275.98 |
| Average True Range (ATR) | 5.11 | 6.62 |
| MACD | 0.39 | 0.80 |
| Stochastic Oscillator | 83.38 | 38.93 |
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
Huntington Ingalls Industries is the largest independent military shipbuilder in the US, spun out from Northrop Grumman in 2011. It operates three segments, two of which are storied shipyards: Ingalls produces non-nuclear-powered ships, including amphibious landing ships and Arleigh Burke-class destroyers, while Newport News produces nuclear-powered ships as the only producer of Gerald Ford-class aircraft carriers and a major subcontractor on Virginia- and Columbia-class nuclear submarines. HII shares production of destroyers and nuclear submarines with General Dynamics' Bath Iron Works and Electric Boat shipyards, respectively. The company's mission technologies segment produces uncrewed sea vessels and provides a range of IT and other services to US government agencies.